

Chen Pei-jer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1588742/publications.pdf>

Version: 2024-02-01

601
papers

39,244
citations

3149

92
h-index

4628

170
g-index

612
all docs

612
docs citations

612
times ranked

28422
citing authors

#	ARTICLE	IF	CITATIONS
1	Metastatic tumor antigen 1 contributes to hepatocarcinogenesis posttranscriptionally through RNA-binding function. <i>Hepatology</i> , 2023, 77, 379-394.	3.6	3
2	Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 424-434.e5.	2.4	9
3	Changing epidemiology of liver disease in Asia: Dual infection of HBV and HCV. <i>Liver International</i> , 2022, 42, 1945-1954.	1.9	9
4	Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2800-2808.	2.4	9
5	Mapping the conformational epitope of a therapeutic monoclonal antibody against HBsAg by in vivo selection of HBV escape variants. <i>Hepatology</i> , 2022, 76, 207-219.	3.6	2
6	Dengue virus RNA detection rates in blood donors correlates with local infection incidences during a dengue outbreak in Taiwan. <i>Journal of Infectious Diseases</i> , 2022, , .	1.9	1
7	Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1579-1587.	0.8	4
8	Safety and dose-escalation study of a targeted oncolytic adenovirus, suradenoturev (OBP-301), in patients with refractory advanced liver cancer: Phase I clinical trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 459-459.	0.8	2
9	Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment. <i>Clinical Infectious Diseases</i> , 2022, 75, 453-459.	2.9	5
10	Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase. <i>American Journal of Gastroenterology</i> , 2022, 117, 748-757.	0.2	15
11	Acute-phase serum amyloid A for early detection of hepatocellular carcinoma in cirrhotic patients with low AFP level. <i>Scientific Reports</i> , 2022, 12, 5799.	1.6	6
12	Phase I Dose-Escalation Study of Tirapazamine Chemoembolization for Unresectable Early- and Intermediate-Stage Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, 926-933.e1.	0.2	3
13	Circulating Virus-Host Chimera DNAs in the Clinical Monitoring of Virus-Related Cancers. <i>Cancers</i> , 2022, 14, 2531.	1.7	1
14	Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis. <i>Viruses</i> , 2022, 14, 1128.	1.5	11
15	Asialo GM1-positive liver-resident CD8 T cells that express CD44 and LFA-1 are essential for immune clearance of hepatitis B virus. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1772-1782.	4.8	14
16	Autophagy restricts mitochondrial DNA damage-induced release of ENDOG (endonuclease G) to regulate genome stability. <i>Autophagy</i> , 2021, 17, 3444-3460.	4.3	27
17	Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy. <i>Journal of Viral Hepatitis</i> , 2021, 28, 887-896.	1.0	7
18	Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance. <i>Cancers</i> , 2021, 13, 2454.	1.7	16

#	ARTICLE	IF	CITATIONS
19	Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2021, 15, 451-458.	1.4	37
20	Investigating the prevalence and clinical effects of hepatitis delta viral infection in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 901-908.	1.5	3
21	Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters. <i>JHEP Reports</i> , 2021, 3, 100254.	2.6	9
22	Robust induction of TRMs by combinatorial nanoshells confers cross-strain sterilizing immunity against lethal influenza viruses. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 299-314.	1.8	5
23	Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan. <i>Journal of Hepatology</i> , 2021, 75, 132-141.	1.8	26
24	Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. <i>JGH Open</i> , 2021, 5, 929-940.	0.7	14
25	Gut microbiota in the innate immunity against hepatitis B virus – implication in age-dependent HBV clearance. <i>Current Opinion in Virology</i> , 2021, 49, 194-202.	2.6	7
26	Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. <i>Journal of the Formosan Medical Association</i> , 2021, , .	0.8	10
27	Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents. <i>Journal of the Formosan Medical Association</i> , 2021, , .	0.8	8
28	Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 908-918.	1.9	20
29	Chapter XX Antiviral Treatment and Cancer Control. <i>Recent Results in Cancer Research</i> , 2021, 217, 325-354.	1.8	0
30	Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, , .	1.9	9
31	Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan. <i>Viruses</i> , 2021, 13, 2294.	1.5	4
32	Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis. <i>Journal of Infectious Diseases</i> , 2020, 221, 589-597.	1.9	11
33	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 569-577.	1.5	18
34	Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 335-344.	0.8	8
35	A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. <i>Gut</i> , 2020, 69, 343-354.	6.1	34
36	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. <i>Liver International</i> , 2020, 40, 758-768.	1.9	24

#	ARTICLE	IF	CITATIONS
37	Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer. <i>International Journal of Cancer</i> , 2020, 147, 901-908.	2.3	5
38	Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. <i>Journal of Hepatology</i> , 2020, 72, 839-846.	1.8	49
39	Gender Difference in the Association Between Metabolic Factors and Hepatocellular Carcinoma. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa036.	1.4	15
40	Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. <i>Cell Reports</i> , 2020, 33, 108254.	2.9	195
41	Secular Trends and Geographic Maps of Hepatitis C Virus Infection among 4 Million Blood Donors in Taiwan from 1999 to 2017. <i>Hepatology Communications</i> , 2020, 4, 1193-1205.	2.0	12
42	Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2020, 59, 1269-1279.	1.3	10
43	Elimination of Hepatitis B in Highly Endemic Settings: Lessons Learned in Taiwan and Challenges Ahead. <i>Viruses</i> , 2020, 12, 815.	1.5	27
44	Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. <i>Hepatology International</i> , 2020, 14, 997-1008.	1.9	18
45	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1019-1040.	0.8	60
46	High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1345-1352.	1.9	6
47	Both hepatitis A and hepatitis D infections may be associated with more advanced liver disease in patients with chronic hepatitis B. <i>Advances in Digestive Medicine</i> , 2020, , .	0.1	3
48	HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice. <i>Journal of Biomedical Science</i> , 2020, 27, 70.	2.6	14
49	Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1871-1875.	0.8	5
50	Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). <i>Journal of Biomedical Science</i> , 2020, 27, 72.	2.6	36
51	Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1476-1482.	0.8	16
52	Performance of commercially available anti-HDV enzyme-linked immunosorbent assays in Taiwan. <i>Virology Journal</i> , 2020, 17, 76.	1.4	8
53	The origin and underlying driving forces of the SARS-CoV-2 outbreak. <i>Journal of Biomedical Science</i> , 2020, 27, 73.	2.6	82
54	Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer. <i>Hepatology</i> , 2020, 72, 2063-2076.	3.6	34

#	ARTICLE	IF	CITATIONS
55	Complement C1q mediates the expansion of periportal hepatic progenitor cells in senescence-associated inflammatory liver. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6717-6725.	3.3	9
56	HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1105-1111.	1.8	43
57	Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials. <i>Hepatology Research</i> , 2020, 50, 1109-1117.	1.8	6
58	Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis. <i>Scientific Reports</i> , 2020, 10, 9180.	1.6	8
59	Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. <i>Journal of Viral Hepatitis</i> , 2020, 27, 568-575.	1.0	21
60	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. <i>Liver Cancer</i> , 2020, 9, 207-220.	4.2	17
61	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1135-1157.	0.8	69
62	Disease burden from foodborne illnesses in Taiwan, 2012-2015. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1372-1381.	0.8	32
63	The role of phylogenetic analysis in clarifying the infection source of a COVID-19 patient. <i>Journal of Infection</i> , 2020, 81, 147-178.	1.7	21
64	Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 20, 480-490.	2.3	66
65	Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. <i>Journal of Clinical Investigation</i> , 2020, 130, 3205-3220.	3.9	38
66	Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 172-181.e1.	2.4	20
67	Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region. <i>Hepatology</i> , 2019, 69, 498-512.	3.6	40
68	Antiviral treatment for hepatitis B in infancy: Still an issue for debate. <i>Journal of Hepatology</i> , 2019, 71, 1264-1265.	1.8	0
69	Specific diacylglycerols generated by hepatic lipogenesis stimulate the oncogenic androgen receptor activity in male hepatocytes. <i>International Journal of Obesity</i> , 2019, 43, 2469-2479.	1.6	6
70	High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. <i>Gastroenterology</i> , 2019, 157, 1518-1529.e3.	0.6	83
71	Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 589-598.	1.9	29
72	Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1620-1625.	1.4	14

#	ARTICLE	IF	CITATIONS
73	Lymphocyte Antigen 6 Complex, Locus C+ Monocytes and Kupffer Cells Orchestrate Liver Immune Responses Against Hepatitis B Virus in Mice. <i>Hepatology</i> , 2019, 69, 2364-2380.	3.6	36
74	Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Children With a Normal Alanine Aminotransferase Level. <i>Hepatology</i> , 2019, 70, 1903-1912.	3.6	11
75	NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2179-2186.	1.4	4
76	Tu1502 - Ledipasvir/Sofosbuvir is Highly Effective and Safe in Patients with Chronic Hepatitis B Virus and Hepatitis C Virus Coinfection: Final Study Results. <i>Gastroenterology</i> , 2019, 156, S-1345.	0.6	3
77	Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1977-1983.	1.4	7
78	Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 184-197.	3.6	9
79	Profile and value of FIB-4 in patients with dual chronic hepatitis C and B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 410-417.	1.4	11
80	Cell and Animal Models for Studying Hepatitis B Virus Infection and Drug Development. <i>Gastroenterology</i> , 2019, 156, 338-354.	0.6	76
81	Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 556-564.	0.8	11
82	Taiwan consensus statement on the management of chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 7-38.	0.8	64
83	Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 331-339.	1.9	11
84	Association Between High Levels of Hepatitis B Core Antibody and Seroclearance of Hepatitis B e Antigen in Individuals With Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1413-1415.	2.4	8
85	Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase. <i>Hepatology</i> , 2019, 69, 1412-1425.	3.6	26
86	Vaccine-induced antigen-specific regulatory T cells attenuate the antiviral immunity against acute influenza virus infection. <i>Mucosal Immunology</i> , 2018, 11, 1239-1253.	2.7	37
87	Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B. <i>Hepatology Communications</i> , 2018, 2, 747-759.	2.0	35
88	Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1690-1698.	1.9	23
89	Fibrosis index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1480-1489.	1.9	19
90	Exploring New Therapies for a Serological Cure of Chronic Hepatitis B. , 2018, , 343-353.		0

#	ARTICLE	IF	CITATIONS
91	Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. <i>Gastroenterology</i> , 2018, 154, 989-997.	0.6	97
92	Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. <i>Journal of Infectious Diseases</i> , 2018, 217, 1193-1201.	1.9	67
93	Acoustic Radiation Force Impulse US Imaging: Liver Stiffness in Patients with Chronic Hepatitis B with and without Antiviral Therapy. <i>Radiology</i> , 2018, 288, 293-299.	3.6	18
94	Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. <i>Journal of Hepatology</i> , 2018, 69, 286-292.	1.8	76
95	The unique antibody suppresses HBV viremia and reduces hepatocarcinogenesis in HBV-transgenic mice. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1779-1781.	1.4	3
96	The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. <i>Virus Research</i> , 2018, 244, 304-310.	1.1	37
97	A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 291-297.	1.4	16
98	Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice. <i>Hepatology</i> , 2018, 67, 586-599.	3.6	29
99	Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 497-504.	0.8	4
100	Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 66, 289-292.	2.9	27
101	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131.	3.6	70
102	Intracellular hepatitis B virus increases hepatic cholesterol deposition in alcoholic fatty liver via hepatitis B core protein. <i>Journal of Lipid Research</i> , 2018, 59, 58-68.	2.0	15
103	Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 710-717.	1.4	28
104	Evaluation of SH-SAW Biosensor in Whole Blood. , 2018, , .		2
105	Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. <i>PLoS ONE</i> , 2018, 13, e0209299.	1.1	13
106	Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. <i>Scientific Reports</i> , 2018, 8, 13699.	1.6	22
107	Genome-wide identification of blood DNA methylation patterns associated with early-onset hepatocellular carcinoma development in hepatitis B carriers. <i>Molecular Carcinogenesis</i> , 2017, 56, 425-435.	1.3	21
108	Management of hepatitis C virus infection in the Asia-Pacific region: an update. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 52-62.	3.7	45

#	ARTICLE	IF	CITATIONS
109	A novel toolbox for the in vitro assay of hepatitis D virus infection. <i>Scientific Reports</i> , 2017, 7, 40199.	1.6	3
110	De novo assembly of highly polymorphic metagenomic data using in situ generated reference sequences and a novel BLAST-based assembly pipeline. <i>BMC Bioinformatics</i> , 2017, 18, 223.	1.2	14
111	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. <i>Hepatology International</i> , 2017, 11, 317-370.	1.9	1,537
112	One-Pot Two-Nanoprobe Assay Uncovers Targeted Glycoprotein Biosignature. <i>Analytical Chemistry</i> , 2017, 89, 3973-3980.	3.2	30
113	Impact of occult hepatitis B on the clinical outcomes of patients with chronic hepatitis C virus infection: A 10-year follow-up. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 697-704.	0.8	14
114	Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 295-299.	0.8	4
115	Hydrodynamic HBV Transfection Mouse Model. <i>Methods in Molecular Biology</i> , 2017, 1540, 227-235.	0.4	7
116	Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2017, 112, 1564-1574.	0.2	44
117	Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. <i>Scientific Reports</i> , 2017, 7, 1728.	1.6	13
118	Genome-wide association analysis identifies a <i>GLUL</i> haplotype for familial hepatitis B virus-related hepatocellular carcinoma. <i>Cancer</i> , 2017, 123, 3966-3976.	2.0	23
119	A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 2405-2413.	3.2	48
120	Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx028.	0.4	43
121	Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. <i>Frontiers in Immunology</i> , 2017, 8, 621.	2.2	48
122	Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study. <i>Anticancer Research</i> , 2017, 37, 2593-2599.	0.5	17
123	Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma Development in Patients With Dual Hepatitis B and C Infection. <i>Medicine (United States)</i> , 2016, 95, e2995.	0.4	18
124	The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2016, 95, e3284.	0.4	43
125	Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 286-294.	1.1	42
126	Hepatitis C viral infection increases the risk of lymphoid neoplasms: A population-based cohort study. <i>Hepatology</i> , 2016, 63, 721-730.	3.6	38

#	ARTICLE	IF	CITATIONS
127	Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma. <i>Hepatology</i> , 2016, 64, 720-731.	3.6	13
128	Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11937-11942.	3.3	37
129	Liver Gene Expression Profiles Correlate with Virus Infection and Response to Interferon Therapy in Chronic Hepatitis B Patients. <i>Scientific Reports</i> , 2016, 6, 31349.	1.6	21
130	Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 953-960.	0.8	6
131	Hepatocellular Carcinoma and Hepatitis C Virus. , 2016, , 109-136.		1
132	Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 49.	1.0	2
133	Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). <i>Journal of Hepatology</i> , 2016, 64, 1011-1019.	1.8	84
134	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016, 10, 1-98.	1.9	1,908
135	Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. <i>Gut</i> , 2016, 65, 658-671.	6.1	104
136	Perspectives on dual hepatitis B and C infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 298-305.	0.8	14
137	Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF- κ B signaling and tumor progression in a woodchuck hepatocellular carcinoma model. <i>Oncotarget</i> , 2016, 7, 47173-47185.	0.8	4
138	Gender disparity in chronic hepatitis B: Mechanisms of sex hormones. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1237-1245.	1.4	101
139	Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. <i>Liver International</i> , 2015, 35, 2155-2166.	1.9	813
140	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. <i>Scientific Reports</i> , 2015, 5, 11710.	1.6	7
141	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. <i>Scientific Reports</i> , 2015, 5, 15255.	1.6	8
142	Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study. <i>Scientific Reports</i> , 2015, 5, 17410.	1.6	13
143	Microevolution of the hepatitis B virus genome in hepatitis B antigen-positive carriers: Comparison of genotypes B and C at various immune stages. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 172-177.	1.4	2
144	Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 184-191.	1.4	7

#	ARTICLE	IF	CITATIONS
145	Development of risk scoring system for stratifying population for hepatocellular carcinoma screening. <i>Hepatology</i> , 2015, 61, 1934-1944.	3.6	46
146	Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan. <i>Journal of Hepatology</i> , 2015, 63, 354-363.	1.8	66
147	Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System. <i>Journal of Infectious Diseases</i> , 2015, 211, 1566-1573.	1.9	18
148	New Insights into the Evolutionary Rate of Hepatitis B Virus at Different Biological Scales. <i>Journal of Virology</i> , 2015, 89, 3512-3522.	1.5	33
149	Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2175-2180.	3.3	175
150	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naïve patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. <i>Gut</i> , 2015, 64, 303-311.	6.1	39
151	Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection. <i>Hepatology International</i> , 2015, 9, 35-42.	1.9	12
152	Contribution of adiponectin and its type 1 receptor to age-related hearing impairment. <i>Neurobiology of Aging</i> , 2015, 36, 2085-2093.	1.5	15
153	Sorafenib Action in Hepatitis B Virus X α Activated Oncogenic Androgen Pathway in Liver through SHP-1. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv190.	3.0	19
154	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7243-7248.	3.3	65
155	Treatment of Liver Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021535.	2.9	241
156	Advanced Hepatic Fibrosis and Steatosis Are Associated With Persistent Alanine Aminotransferase Elevation in Chronic Hepatitis C Patients Negative for Hepatitis C Virus RNA During Pegylated Interferon Plus Ribavirin Therapy. <i>Journal of Infectious Diseases</i> , 2015, 211, 1429-1436.	1.9	7
157	Rapid Fluorescent Lateral-Flow Immunoassay for Hepatitis B Virus Genotyping. <i>Analytical Chemistry</i> , 2015, 87, 5173-5180.	3.2	59
158	Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus Genotyping. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1754-1757.	1.8	62
159	Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model. <i>Cellular and Molecular Immunology</i> , 2015, 12, 317-325.	4.8	28
160	Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 949-960.	1.9	49
161	Feedback regulation of IFN α / β signaling by Axl receptor tyrosine kinase modulates HBV immunity. <i>European Journal of Immunology</i> , 2015, 45, 1696-1705.	1.6	12
162	Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 172-179.	0.8	517

#	ARTICLE	IF	CITATIONS
163	Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection. <i>Clinical Microbiology and Infection</i> , 2015, 21, 197-203.	2.8	98
164	Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor β in female hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2015, 136, 761-770.	2.3	37
165	Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. <i>Gut</i> , 2015, 64, 292-302.	6.1	105
166	Randomized, phase III trial of adjuvant adefovir vs. therapeutic lamivudine in post-operative BCLC stage 0 or A HBV-related HCC: The Taiwan Cooperative Oncology Group T1206 study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4101-4101.	0.8	2
167	A Procalcitonin-Based Algorithm to Guide Antibiotic Therapy in Secondary Peritonitis following Emergency Surgery: A Prospective Study with Propensity Score Matching Analysis. <i>PLoS ONE</i> , 2014, 9, e90539.	1.1	21
168	Circulating Programmed Death-1 as a Marker for Sustained High Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e95870.	1.1	64
169	Tumor Necrosis Factor-Alpha Induced by Hepatitis B Virus Core Mediating the Immune Response for Hepatitis B Viral Clearance in Mice Model. <i>PLoS ONE</i> , 2014, 9, e103008.	1.1	51
170	Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 102-109.	1.4	7
171	A Lego-like swappable fluidic module for bio-chem applications. <i>Sensors and Actuators B: Chemical</i> , 2014, 204, 489-496.	4.0	24
172	Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. <i>Gut</i> , 2014, 63, 1648-1657.	6.1	161
173	Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality. <i>Gut</i> , 2014, 63, 506-514.	6.1	48
174	The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e186.	2.3	319
175	Reply. <i>Hepatology</i> , 2014, 60, 766-767.	3.6	0
176	Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. <i>Liver International</i> , 2014, 34, 174-183.	1.9	68
177	Clinical and virological features of occult hepatitis B in patients with HBsAg seroclearance post-treatment or spontaneously. <i>Liver International</i> , 2014, 34, e71-9.	1.9	14
178	Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: Clinical and mechanistic implications. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1629-1636.	1.4	27
179	The driving circuit of HBx and androgen receptor in HBV-related hepatocarcinogenesis. <i>Gut</i> , 2014, 63, 1688-1689.	6.1	14
180	SC-60, a Dimer-Based Sorafenib Derivative, Shows a Better Anti-Hepatocellular Carcinoma Effect than Sorafenib in a Preclinical Hepatocellular Carcinoma Model. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 27-36.	1.9	7

#	ARTICLE	IF	CITATIONS
181	Anti-Viral Treatment and Cancer Control. Recent Results in Cancer Research, 2014, 193, 269-290.	1.8	10
182	Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology, 2014, 59, 2092-2100.	3.6	235
183	Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. Journal of Gastroenterology, 2014, 49, 356-362.	2.3	14
184	Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1242-1249.	1.4	16
185	Nucleocapsid Phosphorylation and RNA Helicase DDX1 Recruitment Enables Coronavirus Transition from Discontinuous to Continuous Transcription. Cell Host and Microbe, 2014, 16, 462-472.	5.1	165
186	Reduction of HBV replication prolongs the early immunological response to IFN α therapy. Journal of Hepatology, 2014, 60, 54-61.	1.8	75
187	Corrigendum to: "Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia" [Hepatology 2013;59:1073-1080]. Journal of Hepatology, 2014, 60, 902-903.	1.8	0
188	Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy. Gastroenterology, 2014, 146, 442-452.e1.	0.6	123
189	Plasma Adipokines and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus "Infected Carriers: A Prospective Study in Taiwan. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1659-1671.	1.1	20
190	Reduced Toll-Like Receptor 9 Expression on Peripheral CD14 ⁺ Monocytes of Chronic Hepatitis B Patients and its Restoration by Effective Therapy. Antiviral Therapy, 2014, 19, 637-643.	0.6	18
191	Discovery of novel src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. Hepatology, 2014, 59, 190-201.	3.6	63
192	Association of Adjuvant Antiviral Therapy with Risk of Cancer Progression and Deaths in Patients with Hepatitis-B-Virus-Related Hepatocellular Carcinoma following Curative Treatment: A Nationwide Cohort Study. PLoS ONE, 2014, 9, e102051.	1.1	13
193	Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World Journal of Gastroenterology, 2014, 20, 2955.	1.4	22
194	Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World Journal of Gastroenterology, 2014, 20, 11384.	1.4	55
195	Hepatitis B Virus: Pathogenesis and Host Immune Response. , 2014, , 113-132.		0
196	Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer, 2013, 119, 380-387.	2.0	93
197	One step closer to an experimental infection system for Hepatitis B Virus? -- the identification of sodium taurocholate cotransporting peptide as a viral receptor. Cell and Bioscience, 2013, 3, 2.	2.1	6
198	Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. Systematic Reviews, 2013, 2, 37.	2.5	31

#	ARTICLE	IF	CITATIONS
199	Immunocompetent nontransgenic mouse models for studying hepatitis B virus immune responses. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 116-119.	1.4	9
200	Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients. <i>Hepatology International</i> , 2013, 7, 171-179.	1.9	6
201	Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. <i>Hepatology International</i> , 2013, 7, 316-326.	1.9	46
202	A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2013, 20, 729-743.	1.0	23
203	Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). <i>Liver International</i> , 2013, 33, 327-337.	1.9	70
204	A real-time convective PCR machine in a capillary tube instrumented with a CCD-based fluorometer. <i>Sensors and Actuators B: Chemical</i> , 2013, 183, 434-440.	4.0	15
205	Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. <i>Hepatology</i> , 2013, 57, 2135-2142.	3.6	66
206	Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: Current genotyping of EV71 does not reflect their antigenicity. <i>Vaccine</i> , 2013, 31, 425-430.	1.7	41
207	Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. <i>International Journal of Cancer</i> , 2013, 132, 1451-1462.	2.3	21
208	Risk Stratification of Hepatocellular Carcinoma in Hepatitis B Virus e Antigen-Negative Carriers by Combining Viral Biomarkers. <i>Journal of Infectious Diseases</i> , 2013, 208, 584-593.	1.9	45
209	Mother-to-infant transmission of hepatitis B virus infection: Significance of maternal viral load and strategies for intervention. <i>Journal of Hepatology</i> , 2013, 59, 24-30.	1.8	227
210	Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-NFRSF10B (DR5) antibody. <i>British Journal of Pharmacology</i> , 2013, 168, 658-672.	2.7	19
211	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. <i>Hepatology</i> , 2013, 57, 934-943.	3.6	47
212	Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. <i>Gut</i> , 2013, 62, 182.2-184.	6.1	67
213	Antiviral Therapy and Hepatitis B Virus-Related Hepatocellular Carcinoma Recurrence. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 765.	3.8	1
214	Long-Term Follow-up of Children With Postnatal Immunoprophylaxis Failure Who Were Infected With Hepatitis B Virus Surface Antigen Gene Mutant. <i>Journal of Infectious Diseases</i> , 2013, 207, 1047-1057.	1.9	26
215	Predicting clinical outcome in a patient with chronic hepatitis B virus infection. <i>Clinical Liver Disease</i> , 2013, 2, 5-7.	1.0	0
216	Polymerase chain reaction with phase change as intrinsic thermal control. <i>Applied Physics Letters</i> , 2013, 102, 173701.	1.5	6

#	ARTICLE	IF	CITATIONS
217	Liver Sinusoidal Endothelial Cell Lectin Inhibits CTL-Dependent Virus Clearance in Mouse Models of Viral Hepatitis. <i>Journal of Immunology</i> , 2013, 190, 4185-4195.	0.4	21
218	Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7844-7849.	3.3	57
219	Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. <i>Hepatology</i> , 2013, 57, 441-450.	3.6	227
220	Selenium for Sepsis. <i>Critical Care Medicine</i> , 2013, 41, e396.	0.4	1
221	IL-21R Gene Polymorphisms and Serum IL-21 Levels Predict Virological Response to Interferon-Based Therapy in Asian Chronic Hepatitis C Patients. <i>Antiviral Therapy</i> , 2013, 18, 1-8.	0.6	9
222	Reduced Toll-Like Receptor 3 Expression in Chronic Hepatitis B Patients and Its Restoration by Interferon Therapy. <i>Antiviral Therapy</i> , 2013, 18, 877-884.	0.6	40
223	Pegylated Interferon- α 2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis. <i>Annals of Internal Medicine</i> , 2013, 159, 729.	2.0	91
224	Effect of Parenteral Selenium Supplementation in Critically Ill Patients: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e54431.	1.1	90
225	Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection. <i>PLoS ONE</i> , 2013, 8, e55916.	1.1	19
226	Application of Massively Parallel Sequencing to Genetic Diagnosis in Multiplex Families with Idiopathic Sensorineural Hearing Impairment. <i>PLoS ONE</i> , 2013, 8, e57369.	1.1	32
227	Seroprevalence of Hepatitis E Virus Infection among Swine Farmers and the General Population in Rural Taiwan. <i>PLoS ONE</i> , 2013, 8, e67180.	1.1	21
228	ADAR2-Mediated Editing of miR-214 and miR-122 Precursor and Antisense RNA Transcripts in Liver Cancers. <i>PLoS ONE</i> , 2013, 8, e81922.	1.1	30
229	Impact of virologic factors on recurrence-free survival in HBV-related hepatocellular carcinoma after surgical resection: Post hoc analysis from a prospective study with long-term follow-up.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15032-e15032.	0.8	0
230	High-Resolution Melting and Real-Time Pcr for Quantification and Detection of Drug-Resistant HBV Mutants in a Single Amplicon. <i>Antiviral Therapy</i> , 2012, 17, 291-303.	0.6	9
231	Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy. <i>Antiviral Therapy</i> , 2012, 17, 477-484.	0.6	41
232	Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation. <i>Journal of Infectious Diseases</i> , 2012, 206, 1521-1531.	1.9	47
233	Differential Clinical and Virologic Impact of Hepatitis B Virus Genotypes B and C on HIV-Coinfected Patients Receiving Lamivudine-Containing Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2012, 54, 548-555.	2.9	12
234	Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1-Mediated Inhibition of STAT3. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 452-463.	1.9	119

#	ARTICLE	IF	CITATIONS
235	Emerging hepatitis B virus infection in vaccinated populations: a rising concern?. <i>Emerging Microbes and Infections</i> , 2012, 1, 1-4.	3.0	13
236	Serum Hepatitis B Virus-DNA Levels Correlate With Long-term Adverse Outcomes in Spontaneous Hepatitis B e Antigen Seroconverters. <i>Journal of Infectious Diseases</i> , 2012, 205, 54-63.	1.9	51
237	Long-Term Results of a Randomized, Observation-Controlled, Phase III Trial of Adjuvant Interferon Alfa-2b in Hepatocellular Carcinoma After Curative Resection. <i>Annals of Surgery</i> , 2012, 255, 8-17.	2.1	111
238	Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 1059-1067.	0.6	23
239	Fine mapping of hepatitis B virus pre- ϵ deletion and its association with hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1373-1381.	1.9	31
240	Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. <i>Journal of Hepatology</i> , 2012, 57, 720-729.	1.8	158
241	Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia. <i>New England Journal of Medicine</i> , 2012, 367, 716-724.	13.9	274
242	Estrogen Receptor α Represses Transcription of HBV Genes via Interaction With Hepatocyte Nuclear Factor 4 α . <i>Gastroenterology</i> , 2012, 142, 989-998.e4.	0.6	105
243	High Levels of Hepatitis B Surface Antigen Increase Risk of Hepatocellular Carcinoma in Patients With Low HBV Load. <i>Gastroenterology</i> , 2012, 142, 1140-1149.e3.	0.6	469
244	Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity. <i>European Journal of Medicinal Chemistry</i> , 2012, 55, 220-227.	2.6	75
245	Synthesis and biological activity of obatoclax derivatives as novel and potent SHP-1 agonists. <i>European Journal of Medicinal Chemistry</i> , 2012, 56, 127-133.	2.6	21
246	A highly specific ELISA for diagnosis of 2009 influenza A (H1N1) virus infections. <i>Journal of the Formosan Medical Association</i> , 2012, 111, 693-697.	0.8	11
247	Re-evaluation of the Carcinogenic Significance of Hepatitis B Virus Integration in Hepatocarcinogenesis. <i>PLoS ONE</i> , 2012, 7, e40363.	1.1	59
248	Hepatitis B Virus Nucleocapsid but Not Free Core Antigen Controls Viral Clearance in Mice. <i>Journal of Virology</i> , 2012, 86, 9266-9273.	1.5	23
249	Androgen pathway stimulates MicroRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. <i>Hepatology</i> , 2012, 56, 632-643.	3.6	98
250	Influences of tobacco and alcohol use on hepatocellular carcinoma survival. <i>International Journal of Cancer</i> , 2012, 131, 2612-2621.	2.3	52
251	HBeAg(+) and sex ratio of offspring: Evidence form Taiwan's three million newborns. <i>American Journal of Human Biology</i> , 2012, 24, 541-544.	0.8	5
252	Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission. <i>Hepatology International</i> , 2012, 6, 598-605.	1.9	2

#	ARTICLE	IF	CITATIONS
253	Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. <i>Hepatology International</i> , 2012, 6, 591-597.	1.9	18
254	Impact of hepatitis B virus infection on metabolic profiles and modifying factors. <i>Journal of Viral Hepatitis</i> , 2012, 19, e48-57.	1.0	56
255	Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. <i>Biochemical Pharmacology</i> , 2012, 83, 769-777.	2.0	39
256	Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. <i>Biochemical Pharmacology</i> , 2012, 84, 268-277.	2.0	52
257	Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. <i>Hepatology</i> , 2012, 55, 68-76.	3.6	130
258	A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4108-4108.	0.8	16
259	PD-1 Blockage Reverses Immune Dysfunction and Hepatitis B Viral Persistence in a Mouse Animal Model. <i>PLoS ONE</i> , 2012, 7, e39179.	1.1	121
260	Sensitization of hepatocellular carcinoma (HCC) to tigatuzumab (CS-1008), a humanized anti-DR5 antibody, by sorafenib and its derivative SC-49.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14516-e14516.	0.8	0
261	Hepatitis B viraemia: its heritability and association with common genetic variation in the interferon γ signalling pathway. <i>Gut</i> , 2011, 60, 99-107.	6.1	21
262	Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters. <i>Gastroenterology</i> , 2011, 141, 517-525.e2.	0.6	184
263	Role of microRNAs in hepatitis B virus replication and pathogenesis. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2011, 1809, 678-685.	0.9	77
264	Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011, 55, 1041-1048.	1.8	149
265	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. <i>Lancet Oncology</i> , The, 2011, 12, 568-574.	5.1	541
266	Hepatitis B and Deltavirus Infections. , 2011, , 433-440.		0
267	New Variants and Age Shift to High Fatality Groups Contribute to Severe Successive Waves in the 2009 Influenza Pandemic in Taiwan. <i>PLoS ONE</i> , 2011, 6, e28288.	1.1	26
268	HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection. <i>Antiviral Therapy</i> , 2011, 16, 227-235.	0.6	5
269	Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon- α -2A Therapy. <i>Antiviral Therapy</i> , 2011, 16, 629-637.	0.6	91
270	The clinical significance of occult hepatitis B transfusion in Taiwan – a lookâ€back study. <i>Transfusion Medicine</i> , 2011, 21, 33-41.	0.5	34

#	ARTICLE	IF	CITATIONS
271	Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: genotype B vs C. <i>Journal of Viral Hepatitis</i> , 2011, 18, e482-e490.	1.0	21
272	Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2845-2851.	2.6	29
273	Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. <i>Hepatology International</i> , 2011, 5, 814-821.	1.9	13
274	Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12042-12047.	3.3	117
275	Bortezomib Sensitizes HCC Cells to CS-1008, an Antihuman Death Receptor 5 Antibody, through the Inhibition of CIP2A. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 892-901.	1.9	37
276	Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 337, 155-161.	1.3	270
277	Transient Elastography to Assess Hepatic Fibrosis in Hemodialysis Chronic Hepatitis C Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1057-1065.	2.2	77
278	Depletion of β -catenin from mature hepatocytes of mice promotes expansion of hepatic progenitor cells and tumor development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18384-18389.	3.3	33
279	Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3719-3724.	3.3	56
280	Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics. <i>Clinical Cancer Research</i> , 2011, 17, 6914-6923.	3.2	81
281	Long-Term Effect of Interferon Plus Ribavirin on Hepatitis B Surface Antigen Seroclearance in Patients Dually Infected with Hepatitis B and C Viruses. <i>PLoS ONE</i> , 2011, 6, e20752.	1.1	18
282	Establishment of a Knock-In Mouse Model with the SLC26A4 c.919-2A>G Mutation and Characterization of Its Pathology. <i>PLoS ONE</i> , 2011, 6, e22150.	1.1	42
283	Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 1133-1139.	0.6	80
284	Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. <i>Hepatology International</i> , 2010, 4, 386-395.	1.9	47
285	Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. <i>Hepatology International</i> , 2010, 4, 439-474.	1.9	944
286	Increased incidence of gastroesophageal reflux disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2010, 4, 585-593.	1.9	21
287	Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. <i>BMC Cancer</i> , 2010, 10, 620.	1.1	4
288	The evolution of real-time PCR machines to real-time PCR chips. <i>Biosensors and Bioelectronics</i> , 2010, 25, 1820-1824.	5.3	29

#	ARTICLE	IF	CITATIONS
289	Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. <i>Liver International</i> , 2010, 30, 1427-1438.	1.9	35
290	Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. <i>Genes and Immunity</i> , 2010, 11, 87-93.	2.2	41
291	Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 970-977.	1.4	31
292	Molecular and Phylogenetic Analyses Suggest an Additional Hepatitis B Virus Genotype. <i>PLoS ONE</i> , 2010, 5, e9297.	1.1	123
293	Mutations in the <i>OTOF</i> Gene in Taiwanese Patients with Auditory Neuropathy. <i>Audiology and Neuro-Otology</i> , 2010, 15, 364-374.	0.6	52
294	Distinct Hepatitis B Virus Dynamics in the Immunotolerant and Early Immunoclearance Phases. <i>Journal of Virology</i> , 2010, 84, 3454-3463.	1.5	81
295	Hepatitis C Virus Seromarkers and Subsequent Risk of Hepatocellular Carcinoma: Long-Term Predictors From a Community-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4587-4593.	0.8	150
296	Phenotypic Analyses and Mutation Screening of the <i>SLC26A4</i> and <i>FOXI1</i> Genes in 101 Taiwanese Families with Bilateral Nonsyndromic Enlarged Vestibular Aqueduct (DFNB4) or Pendred Syndrome. <i>Audiology and Neuro-Otology</i> , 2010, 15, 57-66.	0.6	60
297	Pegylated Interferon Alfa-2a Monotherapy for Hemodialysis Patients with Acute Hepatitis C. <i>Clinical Infectious Diseases</i> , 2010, 51, 541-549.	2.9	36
298	Phosphorylation of Serine 177 of the Small Hepatitis Delta Antigen Regulates Viral Antigenomic RNA Replication by Interacting with the Processive RNA Polymerase II. <i>Journal of Virology</i> , 2010, 84, 1430-1438.	1.5	32
299	Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Oncology</i> , 2010, 28, 2437-2444.	0.8	249
300	HBsAg Profiles in Patients Receiving Peginterferon Alfa-2a plus Ribavirin for the Treatment of Dual Chronic Infection with Hepatitis B and C Viruses. <i>Journal of Infectious Diseases</i> , 2010, 202, 86-92.	1.9	46
301	Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3. <i>Clinical Cancer Research</i> , 2010, 16, 5189-5199.	3.2	155
302	Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 9340-9345.	3.3	69
303	Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 14769-14774.	3.3	33
304	No Increase in Prevalence of Hepatitis B Surface Antigen Mutant in a Population of Children and Adolescents Who Were Fully Covered by Universal Infant Immunization. <i>Journal of Infectious Diseases</i> , 2010, 201, 1192-1200.	1.9	77
305	The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. <i>Kidney International</i> , 2010, 78, 103-109.	2.6	32
306	Gender Disparity of Hepatocellular Carcinoma: The Roles of Sex Hormones. <i>Oncology</i> , 2010, 78, 172-179.	0.9	232

#	ARTICLE	IF	CITATIONS
307	Recent Advances in the Research of Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Advances in Cancer Research</i> , 2010, 108, 21-72.	1.9	86
308	Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. <i>Journal of Hepatology</i> , 2010, 52, 88-95.	1.8	64
309	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2010, 53, 126-131.	1.8	124
310	Pegylated interferon α -2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. <i>Gut</i> , 2009, 58, 314-316.	6.1	27
311	Epidemiologic Features of Kawasaki Disease in Taiwan, 2003–2006. <i>Pediatrics</i> , 2009, 123, e401-e405.	1.0	207
312	Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway. <i>Journal of Biological Chemistry</i> , 2009, 284, 11121-11133.	1.6	79
313	Glycogen Synthase Kinase-3 Regulates the Phosphorylation of Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein and Viral Replication. <i>Journal of Biological Chemistry</i> , 2009, 284, 5229-5239.	1.6	168
314	Oncolytic virotherapy for advanced liver tumours. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 1238-1247.	1.6	15
315	Hepatitis B virus X protein enhances the transcriptional activity of the androgen receptor through c-Src and glycogen synthase kinase-3 β kinase pathways. <i>Hepatology</i> , 2009, 49, 1515-1524.	3.6	95
316	Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy. <i>Hepatology</i> , 2009, 50, 654-655.	3.6	3
317	Identification of androgen response elements in the enhancer I of hepatitis B virus: A mechanism for sex disparity in chronic hepatitis B. <i>Hepatology</i> , 2009, 50, 1392-1402.	3.6	151
318	Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus. <i>Journal of Medical Virology</i> , 2009, 81, 588-593.	2.5	6
319	Application of SNaPshot multiplex assays for simultaneous multigene mutation screening in patients with idiopathic sensorineural hearing impairment. <i>Laryngoscope</i> , 2009, 119, 2411-2416.	1.1	18
320	A micro circulating PCR chip using a suction-type membrane for fluidic transport. <i>Biomedical Microdevices</i> , 2009, 11, 359-367.	1.4	24
321	High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. <i>Hepatology International</i> , 2009, 3, 364-370.	1.9	31
322	Dual chronic hepatitis B virus and hepatitis C virus infection. <i>Hepatology International</i> , 2009, 3, 517-525.	1.9	49
323	Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based study. <i>European Journal of Human Genetics</i> , 2009, 17, 1250-1259.	1.4	17
324	A miniaturized quantitative polymerase chain reaction system for DNA amplification and detection. <i>Sensors and Actuators B: Chemical</i> , 2009, 141, 329-337.	4.0	45

#	ARTICLE	IF	CITATIONS
325	Synergistic Effect of Radiation and Interleukin-6 on Hepatitis B Virus Reactivation in Liver Through STAT3 Signaling Pathway. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1545-1552.	0.4	25
326	Structure-Based Discovery of Triphenylmethane Derivatives as Inhibitors of Hepatitis C Virus Helicase. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2716-2723.	2.9	55
327	Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage. <i>Journal of Hepatology</i> , 2009, 50, 958-968.	1.8	144
328	Reactivation of hepatitis B virus in an inactive hepatitis B carrier with glucocorticoid pulse therapy. <i>Digestive and Liver Disease</i> , 2009, 41, 322-323.	0.4	3
329	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 598-604.	0.2	34
330	MicroRNA-18a Prevents Estrogen Receptor- α Expression, Promoting Proliferation of Hepatocellular Carcinoma Cells. <i>Gastroenterology</i> , 2009, 136, 683-693.	0.6	250
331	Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses. <i>Gastroenterology</i> , 2009, 136, 496-504.e3.	0.6	211
332	Hepatitis B Virus Basal Core Promoter Mutation and DNA Load Correlate with Expression of Hepatitis B Core Antigen in Patients with Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2009, 199, 742-749.	1.9	28
333	IL10 and IL10 Receptor Gene Variation and Outcomes After Unrelated and Related Hematopoietic Cell Transplantation. <i>Transplantation</i> , 2009, 87, 704-710.	0.5	27
334	Research Highlights: Pharmacogenomics of chronic hepatitis C. <i>Pharmacogenomics</i> , 2009, 10, 1039-1042.	0.6	0
335	Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. <i>Antiviral Therapy</i> , 2009, 14, 1157-1163.	0.6	29
336	Association of Lipid Profiles With Hepatitis C Viral Load in Chronic Hepatitis C Patients With Genotype 1 or 2 Infection. <i>American Journal of Gastroenterology</i> , 2009, 104, 598-604.	0.2	6
337	Lamivudine and Hepatitis B Reactivation. <i>Annals of Internal Medicine</i> , 2009, 151, 141.	2.0	0
338	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009, 14, 45-54.	0.6	10
339	Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. <i>Antiviral Therapy</i> , 2009, 14, 45-54.	0.6	35
340	Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. <i>Antiviral Therapy</i> , 2009, 14, 203-210.	0.6	12
341	High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. <i>Liver International</i> , 2008, 28, 271-277.	1.9	86
342	Metabolic profiles in patients with chronic hepatitis C: a case-control study. <i>Hepatology International</i> , 2008, 2, 250-257.	1.9	33

#	ARTICLE	IF	CITATIONS
343	A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. <i>Hepatology</i> , 2008, 47, 844-853.	3.6	277
344	Viral hepatocarcinogenesis: from infection to cancer. <i>Liver International</i> , 2008, 28, 175-188.	1.9	95
345	Interferon treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan. <i>Liver International</i> , 2008, 28, 1288-1297.	1.9	41
346	A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients. <i>Liver International</i> , 2008, 28, 1034-1041.	1.9	19
347	A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus. <i>Transfusion</i> , 2008, 48, 1198-1206.	0.8	57
348	Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan. <i>Gastroenterology</i> , 2008, 135, 111-121.	0.6	492
349	The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. <i>Journal of Hepatology</i> , 2008, 49, 899-907.	1.8	18
350	Genetic analysis and evaluation of the reassortment of influenza B viruses isolated in Taiwan during the 2004-2005 and 2006-2007 epidemics. <i>Virus Research</i> , 2008, 131, 243-249.	1.1	21
351	The circulation of subgenogroups B5 and C5 of enterovirus 71 in Taiwan from 2006 to 2007. <i>Virus Research</i> , 2008, 137, 206-212.	1.1	61
352	Physician-scientist: Attitude of Graduates of Clinical Medicine Graduate Schools. <i>Journal of the Formosan Medical Association</i> , 2008, 107, 519-526.	0.8	5
353	Disease Progression in a Patient with Nonalcoholic Steatohepatitis. <i>Journal of the Formosan Medical Association</i> , 2008, 107, 816-821.	0.8	8
354	Pegylated Interferon-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2008, 47, 1260-1269.	2.9	177
355	Prospective Mutation Screening of Three Common Deafness Genes in a Large Taiwanese Cohort with Idiopathic Bilateral Sensorineural Hearing Impairment Reveals a Difference in the Results between Families from Hospitals and Those from Rehabilitation Facilities. <i>Audiology and Neuro-Otology</i> , 2008, 13, 172-181.	0.6	34
356	Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1134-1143.	3.0	549
357	Acute Fatty Liver of Pregnancy with Concurrent Acute Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2008, 103, 2663-2665.	0.2	0
358	Genetic and Epidemiological Analysis of Influenza Virus Epidemics in Taiwan during 2003 to 2006. <i>Journal of Clinical Microbiology</i> , 2008, 46, 1426-1434.	1.8	25
359	Nucleolar Targeting of Hepatitis Delta Antigen Abolishes Its Ability To Initiate Viral Antigenomic RNA Replication. <i>Journal of Virology</i> , 2008, 82, 692-699.	1.5	25
360	Humoral and Cellular Immune Responses to a Hepatitis B Vaccine Booster 15-18 Years after Neonatal Immunization. <i>Journal of Infectious Diseases</i> , 2008, 197, 1419-1426.	1.9	175

#	ARTICLE	IF	CITATIONS
361	ERK1/2-Mediated Phosphorylation of Small Hepatitis Delta Antigen at Serine 177 Enhances Hepatitis Delta Virus Antigenomic RNA Replication. <i>Journal of Virology</i> , 2008, 82, 9345-9358.	1.5	21
362	Esophageal Varices: Noninvasive Diagnosis with Duplex Doppler US in Patients with Compensated Cirrhosis. <i>Radiology</i> , 2008, 248, 132-139.	3.6	29
363	Predominance of Genetic Diagnosis and Imaging Results as Predictors in Determining the Speech Perception Performance Outcome After Cochlear Implantation in Children. <i>JAMA Pediatrics</i> , 2008, 162, 269.	3.6	49
364	Regulatory T cells alleviate allergic airway hyperresponsiveness by modulating angiogenesis of airway remodelling via Notch signaling pathway. <i>FASEB Journal</i> , 2008, 22, 710.11.	0.2	0
365	Hepatitis B viral genotype in Taiwanese patients with acute hepatitis B. <i>Hepato-Gastroenterology</i> , 2008, 55, 633-5.	0.5	1
366	Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis. <i>Antiviral Therapy</i> , 2008, 13, 469-80.	0.6	3
367	Hepatitis B virus Quantification and Detection of YMDD Mutants in a Single Reaction by Real-Time PCR and Annealing Curve Analysis. <i>Antiviral Therapy</i> , 2008, 13, 469-480.	0.6	8
368	Impact of Hepatitis D Virus Infection on the Long-Term Outcomes of Patients with Hepatitis B Virus and HIV Coinfection in the Era of Highly Active Antiretroviral Therapy: A Matched Cohort Study. <i>Clinical Infectious Diseases</i> , 2007, 44, 988-995.	2.9	79
369	Pegylated interferon α -2a versus standard interferon α -2a for treatment-naïve dialysis patients with chronic hepatitis C: a randomised study. <i>Gut</i> , 2007, 57, 525-530.	6.1	69
370	Ectopic Liver with Hepatocellular Carcinoma in the Peritoneum. <i>American Journal of Roentgenology</i> , 2007, 188, W206-W207.	1.0	8
371	OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. <i>Nucleic Acids Research</i> , 2007, 35, D727-D731.	6.5	99
372	Evolution of Hepatitis B Serological Markers in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2007, 45, 1221-1229.	2.9	77
373	Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 2571-2578.	3.3	126
374	Clinical Impact of GB Virus C Viremia on Patients with HIV Type 1 Infection in the Era of Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2007, 44, 584-590.	2.9	11
375	Early Viral Kinetics during Treatment of Chronic Hepatitis C Virus Infection with Pegylated Interferon Alpha plus Ribavirin in Taiwan. <i>Intervirology</i> , 2007, 50, 310-315.	1.2	17
376	Radiation-Induced Hepatitis B Virus Reactivation in Liver Mediated by the Bystander Effect from Irradiated Endothelial Cells. <i>Clinical Cancer Research</i> , 2007, 13, 851-857.	3.2	94
377	Prevalence and Clinical Features of the Mitochondrial m.1555A>G Mutation in Taiwanese Patients with Idiopathic Sensorineural Hearing Loss and Association of Haplogroup F with Low Penetrance in Three Families. <i>Ear and Hearing</i> , 2007, 28, 332-342.	1.0	28
378	Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models. <i>Vaccine</i> , 2007, 25, 3038-3040.	1.7	26

#	ARTICLE	IF	CITATIONS
379	Noninvasive Diagnosis of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Splenic Doppler Impedance Index. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1199-1206.e1.	2.4	29
380	Viremia Profiles in Children With Chronic Hepatitis B Virus Infection and Spontaneous e Antigen Seroconversion. <i>Gastroenterology</i> , 2007, 132, 2340-2345.	0.6	72
381	Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2007, 120, 1610-1617.	2.3	21
382	Hepatitis B viral factors in HBeAg-Negative carriers with persistently normal serum alanine aminotransferase levels. <i>Hepatology</i> , 2007, 45, 1193-1198.	3.6	103
383	High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users. <i>Journal of Medical Virology</i> , 2007, 79, 1674-1678.	2.5	25
384	Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1098-1103.	1.4	76
385	Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1494-1499.	1.4	22
386	How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 788-793.	1.4	327
387	Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 64-69.	1.0	22
388	Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 153-160.	1.0	16
389	Subgenotypes of hepatitis B virus genotype C do not correlate with disease progression of chronic hepatitis B in Taiwan. <i>Liver International</i> , 2007, 27, 983-988.	1.9	14
390	Suppressor and effector T cells exhibit differential migration capacity. <i>FASEB Journal</i> , 2007, 21, A773.	0.2	0
391	Regulatory T cells alleviate allergic airway hyperresponsiveness by modulating angiogenesis in airway remodelling. <i>FASEB Journal</i> , 2007, 21, A762.	0.2	0
392	Epidemiology of HBV infection in Asian blood donors: Emphasis on occult HBV infection and the role of NAT. <i>Journal of Clinical Virology</i> , 2006, 36, S33-S44.	1.6	105
393	Natural Course and Treatment of Hepatitis D Virus Infection. <i>Journal of the Formosan Medical Association</i> , 2006, 105, 869-881.	0.8	39
394	High Prevalence and Mapping of Pre-S Deletion in Hepatitis B Virus Carriers With Progressive Liver Diseases. <i>Gastroenterology</i> , 2006, 130, 1153-1168.	0.6	257
395	Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma.. <i>Clinical Cancer Research</i> , 2006, 12, 1097-1108.	3.2	52
396	Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. <i>European Journal of Cancer</i> , 2006, 42, 2524-2529.	1.3	67

#	ARTICLE	IF	CITATIONS
397	Genetic predisposition of responsiveness to therapy for chronic hepatitis C. <i>Pharmacogenomics</i> , 2006, 7, 697-709.	0.6	31
398	Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. <i>Journal of Hepatology</i> , 2006, 44, 39-46.	1.8	105
399	Genetic mutation in hepatic adenoma: Seeing is believing. <i>Journal of Hepatology</i> , 2006, 45, 767-769.	1.8	9
400	Higher cut-off index value of immunoglobulin M antibody to hepatitis B core antigen in Taiwanese patients with hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 859-862.	1.4	16
401	Viral factors correlate with hepatitis B e antigen seroconversion in patients with chronic hepatitis B. <i>Liver International</i> , 2006, 26, 949-955.	1.9	40
402	Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants. <i>Journal of Viral Hepatitis</i> , 2006, 13, 387-395.	1.0	14
403	Genetic structural differences between responders and non-responders to interferon therapy for chronic hepatitis-B patients. <i>Journal of Human Genetics</i> , 2006, 51, 984-991.	1.1	6
404	Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 654-664.	1.1	12
405	Interferon α -2b with and without ribavirin in the treatment of hepatitis B e antigen α -positive chronic hepatitis B: A randomized study. <i>Hepatology</i> , 2006, 43, 742-749.	3.6	41
406	Prospect of Individualized Medicine in Chronic Hepatitis C Therapy by Pharmacogenomics. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2006, 4, 157-167.	0.3	3
407	Role of Hepatitis B Virus Precore/Core Promoter Mutations and Serum Viral Load on Noncirrhotic Hepatocellular Carcinoma: A Case α -Control Study. <i>Journal of Infectious Diseases</i> , 2006, 194, 594-599.	1.9	125
408	Lack of Association between Infection with a Novel Human Coronavirus (HCoV), HCoV α -NH, and Kawasaki Disease in Taiwan. <i>Journal of Infectious Diseases</i> , 2006, 193, 283-286.	1.9	77
409	Role of Hepatitis B Viral Load and Basal Core Promoter Mutation in Hepatocellular Carcinoma in Hepatitis B Carriers. <i>Journal of Infectious Diseases</i> , 2006, 193, 1258-1265.	1.9	163
410	Evolution of Hepatitis B virus in an acute hepatitis B patient co-infected with genotypes B and C. <i>Journal of General Virology</i> , 2006, 87, 39-49.	1.3	30
411	An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 17862-17867.	3.3	265
412	Development of Vaccines and Passive Immunotherapy Against Sars Coronavirus Using Mouse and Scid-PBL/hu Mouse Models. <i>Advances in Experimental Medicine and Biology</i> , 2006, 581, 561-566.	0.8	10
413	Percutaneous Ethanol Injection Versus Surgical Resection for the Treatment of Small Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2005, 242, 36-42.	2.1	180
414	Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor 1 α genotype of donor. <i>Blood</i> , 2005, 106, 3995-4001.	0.6	74

#	ARTICLE	IF	CITATIONS
415	Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. <i>Liver International</i> , 2005, 25, 564-570.	1.9	68
416	Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan. <i>Liver International</i> , 2005, 25, 214-219.	1.9	21
417	Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. <i>Liver International</i> , 2005, 25, 752-759.	1.9	29
418	Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients. <i>Pediatrics International</i> , 2005, 47, 372-377.	0.2	18
419	Common Clinical Features of Children With Enlarged Vestibular Aqueduct and Mondini Dysplasia. <i>Laryngoscope</i> , 2005, 115, 132-137.	1.1	64
420	Prevalent SLC26A4 Mutations in Patients with Enlarged Vestibular Aqueduct and/or Mondini Dysplasia: A Unique Spectrum of Mutations in Taiwan, Including a Frequent Founder Mutation. <i>Laryngoscope</i> , 2005, 115, 1060-1064.	1.1	75
421	Molecular genetic evidence supporting a novel human hepatocellular carcinoma tumor suppressor locus at 13q12.11. <i>Genes Chromosomes and Cancer</i> , 2005, 44, 320-328.	1.5	29
422	Epigenetic activation of $\alpha 4$, $\beta 2$ and $\beta 6$ integrins involved in cell migration in trichostatin A-treated Hep3B cells. <i>Journal of Biomedical Science</i> , 2005, 12, 803-813.	2.6	19
423	Application of Hepatitis B Virus Genotyping and Phylogenetic Analysis in Intrafamilial Transmission of Hepatitis B Virus. <i>Clinical Infectious Diseases</i> , 2005, 41, 1576-1581.	2.9	39
424	Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men. <i>Journal of the National Cancer Institute</i> , 2005, 97, 265-272.	3.0	518
425	Intratypic Recombination among Lineages of Type 1 Vaccine-Derived Poliovirus Emerging during Chronic Infection of an Immunodeficient Patient. <i>Journal of Virology</i> , 2005, 79, 12623-12634.	1.5	89
426	Specificity of SLC26A4 Mutations in the Pathogenesis of Inner Ear Malformations. <i>Audiology and Neuro-Otology</i> , 2005, 10, 234-242.	0.6	18
427	Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. <i>International Journal of Epidemiology</i> , 2005, 34, 1310-1318.	0.9	99
428	Laboratory-Based Surveillance and Molecular Epidemiology of Influenza Virus in Taiwan. <i>Journal of Clinical Microbiology</i> , 2005, 43, 1651-1661.	1.8	62
429	Immunofluorescence Assay for Detection of the Nucleocapsid Antigen of the Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus in Cells Derived from Throat Wash Samples of Patients with SARS. <i>Journal of Clinical Microbiology</i> , 2005, 43, 2444-2448.	1.8	42
430	Therapy for Ulcerative Colitis: Nonresponsive Patients May Need Anti-Helminth Therapy. <i>Gastroenterology</i> , 2005, 129, 768-769.	0.6	7
431	Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 43, 235-242.	1.8	64
432	The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice. <i>Vaccine</i> , 2005, 23, 2269-2272.	1.7	48

#	ARTICLE	IF	CITATIONS
433	RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. <i>Gastroenterology</i> , 2005, 128, 708-716.	0.6	97
434	Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. <i>World Journal of Gastroenterology</i> , 2005, 11, 5283.	1.4	18
435	Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. <i>Antiviral Therapy</i> , 2005, 10, 405-15.	0.6	6
436	Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. <i>Journal of the Formosan Medical Association</i> , 2005, 104, 783-91.	0.8	38
437	Influence of Metabolic Syndrome, Viral Genotype and Antiviral Therapy on Superimposed Fatty Liver Disease in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2005, 10, 405-415.	0.6	30
438	Patient Data, Early SARS Epidemic, Taiwan. <i>Emerging Infectious Diseases</i> , 2004, 10, 489-493.	2.0	59
439	Infection Control and SARS Transmission among Healthcare Workers, Taiwan. <i>Emerging Infectious Diseases</i> , 2004, 10, 895-898.	2.0	50
440	SARS Exposure and Emergency Department Workers. <i>Emerging Infectious Diseases</i> , 2004, 10, 1117-1119.	2.0	28
441	Induction of Humoral and Cellular Immune Responses to Hepatitis Delta Virus Through DNA Immunization in BALB/c Mice. , 2004, 96, 111-128.		0
442	Vaccination with a DNA Vaccine Encoding Herpes Simplex Virus Type 1 VP22 Linked to Antigen Generates Long-Term Antigen-Specific CD8-Positive Memory T Cells and Protective Immunity. <i>Human Gene Therapy</i> , 2004, 15, 167-177.	1.4	61
443	Epidemiologic Features of Kawasaki Disease in Taiwan, 1996-2002. <i>Pediatrics</i> , 2004, 114, e678-e682.	1.0	76
444	Clustering of Minimal Deleted Regions Reveals Distinct Genetic Pathways of Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2004, 64, 3030-3036.	0.4	38
445	Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: Molecular epidemiology and genome evolution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 2542-2547.	3.3	121
446	Generation and Characterization of DNA Vaccines Targeting the Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus. <i>Journal of Virology</i> , 2004, 78, 4638-4645.	1.5	164
447	Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy. <i>Liver International</i> , 2004, 24, 9-15.	1.9	14
448	The small delta antigen of hepatitis delta virus is an acetylated protein and acetylation of lysine 72 may influence its cellular localization and viral RNA synthesis. <i>Virology</i> , 2004, 319, 60-70.	1.1	59
449	Allelic loss of chromosome 4q21 associates with hepatitis B Virus-related hepatocarcinogenesis and elevated alpha-fetoprotein. <i>Hepatology</i> , 2004, 40, 847-854.	3.6	6
450	A forgotten population with chronic hepatitis C infection: Subjects coinfecting with hepatitis B virus. <i>Hepatology</i> , 2004, 40, 266-266.	3.6	12

#	ARTICLE	IF	CITATIONS
451	Origin of serum hepatitis B virus in acute exacerbation: Comparison with HBV in the liver and from other exacerbation. <i>Hepatology</i> , 2004, 40, 310-317.	3.6	22
452	Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. <i>Journal of Medical Virology</i> , 2004, 72, 363-369.	2.5	159
453	Precore/core promoter mutations and genotypes of hepatitis B virus in chronic hepatitis B patients with fulminant or subfulminant hepatitis. <i>Journal of Medical Virology</i> , 2004, 72, 545-550.	2.5	42
454	Genotypic dominance and novel recombinations in HBV genotype B and C co-infected intravenous drug users. <i>Journal of Medical Virology</i> , 2004, 73, 13-22.	2.5	43
455	Evaluation of antibody responses against SARS coronaviral nucleocapsid or spike proteins by immunoblotting or ELISA. <i>Journal of Medical Virology</i> , 2004, 73, 338-346.	2.5	64
456	Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion. <i>Journal of Medical Virology</i> , 2004, 74, 237-245.	2.5	23
457	High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users. <i>Journal of Medical Virology</i> , 2004, 74, 536-542.	2.5	40
458	Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 64-71.	2.4	50
459	Heterogeneity of hereditary persistence of alpha-fetoprotein. <i>Gastroenterology</i> , 2004, 127, 687.	0.6	4
460	Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CLprotease: basis for the in vitro screening of anti-SARS drugs. <i>FEBS Letters</i> , 2004, 574, 131-137.	1.3	37
461	Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2004, 315, 950-958.	1.0	143
462	Hepatitis C virus NS3 RNA helicase activity is modulated by the two domains of NS3 and NS4A. <i>Biochemical and Biophysical Research Communications</i> , 2004, 317, 211-217.	1.0	39
463	Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. <i>Vaccine</i> , 2004, 22, 3993-4001.	1.7	58
464	Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. <i>Journal of Hepatology</i> , 2004, 41, 659-666.	1.8	194
465	Allelic loss of chromosome 4q21-23 associates with hepatitis B virus-related hepatocarcinogenesis and elevated alpha-fetoprotein. <i>Hepatology</i> , 2004, 40, 847-854.	3.6	24
466	Association of IL-10 and IL-10 Receptor Gene Polymorphisms and Graft-Versus-Host Disease Following Hematopoietic Cell Transplantation. <i>Blood</i> , 2004, 104, 421-421.	0.6	3
467	End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2004, 10, 3574.	1.4	14
468	Lack of Interferon Sensitivity-Determining Region in the Genome of Hepatitis B Virus Genotype Ba. <i>Antiviral Therapy</i> , 2004, 9, 895-903.	0.6	10

#	ARTICLE	IF	CITATIONS
469	Relation of an Interleukin-10 Promoter Polymorphism to Graft-versus-Host Disease and Survival after Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2003, 349, 2201-2210.	13.9	360
470	Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. <i>Hepatology</i> , 2003, 37, 568-576.	3.6	111
471	Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. <i>Hepatology</i> , 2003, 37, 1320-1328.	3.6	256
472	Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors. <i>Journal of Gene Medicine</i> , 2003, 5, 386-398.	1.4	25
473	Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. <i>Hepatology</i> , 2003, 38, 1393-1400.	3.6	96
474	Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis-C virus infection in Taiwan: a prospective study. <i>Liver International</i> , 2003, 23, 148-155.	1.9	20
475	A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. <i>Gastroenterology</i> , 2003, 124, 80-90.	0.6	68
476	Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. <i>Gastroenterology</i> , 2003, 124, 327-334.	0.6	499
477	Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection. <i>Journal of Hepatology</i> , 2003, 39, 1028-1035.	1.8	17
478	Polymorphisms in XRCC1 and Glutathione S-Transferase Genes and Hepatitis B-Related Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1485-1488.	3.0	100
479	Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C. <i>Journal of Endocrinology</i> , 2003, 178, 457-465.	1.2	34
480	A prospect for pharmacogenomics in the interferon therapy of chronic viral hepatitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 149-151.	1.3	6
481	SEN Virus Infection in Patients with Chronic Hepatitis C: Preferential Coinfection with Hepatitis C Genotype 2a and No Effect on Response to Therapy with Interferon plus Ribavirin. <i>Journal of Infectious Diseases</i> , 2003, 187, 307-310.	1.9	20
482	Microbiologic Characteristics, Serologic Responses, and Clinical Manifestations in Severe Acute Respiratory Syndrome, Taiwan1. <i>Emerging Infectious Diseases</i> , 2003, 9, 1163-1167.	2.0	66
483	The Double-stranded RNA-activated Kinase, PKR, Can Phosphorylate Hepatitis D Virus Small Delta Antigen at Functional Serine and Threonine Residues. <i>Journal of Biological Chemistry</i> , 2002, 277, 33058-33067.	1.6	38
484	Hepatitis D Virus Genotypes in Intravenous Drug Users in Taiwan: Decreasing Prevalence and Lack of Correlation with Hepatitis B Virus Genotypes. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3047-3049.	1.8	37
485	Prevalence and Implication of a Newly Identified Infectious Agent (SEN Virus) in Taiwan. <i>Journal of Infectious Diseases</i> , 2002, 185, 389-392.	1.9	48
486	Genotypes and Clinical Phenotypes of Hepatitis B Virus in Patients with Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1207-1209.	1.8	178

#	ARTICLE	IF	CITATIONS
487	Occult Hepatitis B Virus Infection and Clinical Outcomes of Patients with Chronic Hepatitis C. <i>Journal of Clinical Microbiology</i> , 2002, 40, 4068-4071.	1.8	149
488	Clinical and Virological Aspects of Blood Donors Infected with Hepatitis B Virus Genotypes B and C. <i>Journal of Clinical Microbiology</i> , 2002, 40, 22-25.	1.8	83
489	p53 gene and Wnt signaling in benign neoplasms: β -catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. <i>Hepatology</i> , 2002, 36, 927-935.	3.6	6
490	Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2002, 347, 168-174.	13.9	1,170
491	Simultaneous genotyping of single nucleotide polymorphisms in the IL-1 gene complex by multiplex polymerase chain reaction-restriction fragment length polymorphism. <i>Journal of Immunological Methods</i> , 2002, 267, 151-156.	0.6	22
492	Naturally occurring hepatitis B surface gene variants in chronic hepatitis B virus infection: Correlation with viral serotypes and clinical stages of liver disease. <i>Journal of Medical Virology</i> , 2002, 68, 50-59.	2.5	40
493	Sequence analysis of pre-S/surface and pre-core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection. <i>Journal of Medical Virology</i> , 2002, 68, 216-220.	2.5	39
494	Characterization of integration patterns and flanking cellular sequences of hepatitis B virus in childhood hepatocellular carcinomas. <i>Journal of Medical Virology</i> , 2002, 68, 513-521.	2.5	23
495	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , 2002, 36, 1416-1424.	3.6	30
496	Definition of three minimal deleted regions by comprehensive allelotyping and mutational screening of FHIT, p16INK4A, and p19ARF genes in nasopharyngeal carcinoma. <i>Cancer</i> , 2002, 94, 1987-1996.	2.0	20
497	Chromosomal analysis of hepatic adenoma and focal nodular hyperplasia by comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 138-143.	1.5	38
498	Molecular epidemiology of hepatitis B viral serotypes and genotypes in taiwan. <i>Journal of Biomedical Science</i> , 2002, 9, 166-170.	2.6	33
499	Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2002, 37, 283-287.	2.3	39
500	Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers. <i>Transfusion</i> , 2002, 42, 1592-1597.	0.8	76
501	Minimal role of GB virus-C/hepatitis G virus in fulminant and subfulminant hepatitis in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 352-357.	1.4	15
502	Comparison of two methods for quantification of hepatitis B viral DNA. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 423-426.	1.4	16
503	Androgen receptor exon 1 CAG repeat length and risk of hepatocellular carcinoma in women. <i>Hepatology</i> , 2002, 36, 156-163.	3.6	28
504	Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. <i>Hepatology</i> , 2002, 36, 1416-1424.	3.6	41

#	ARTICLE	IF	CITATIONS
505	Dominance of functional androgen receptor allele with longer CAG repeat in hepatitis B virus-related female hepatocarcinogenesis. <i>Cancer Research</i> , 2002, 62, 4346-51.	0.4	22
506	Amebic Liver Abscess and Human Immunodeficiency Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2001, 33, 64-68.	1.1	27
507	Ribavirin enhances interferon- β levels in patients with chronic hepatitis C treated with interferon- α . <i>Journal of Biomedical Science</i> , 2001, 8, 484-491.	2.6	7
508	Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: A 4-year experience. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2001, 16, 1001-1008.	1.4	40
509	Molecular cloning and expression of woodchuck granulocyte-macrophage colony stimulating factor. <i>Journal of Medical Virology</i> , 2001, 65, 567-575.	2.5	9
510	Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. <i>Hepatology</i> , 2001, 34, 583-589.	3.6	50
511	Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus. <i>Hepatology</i> , 2001, 34, 817-823.	3.6	73
512	The Conserved Serine 177 in the Delta Antigen of Hepatitis Delta Virus Is One Putative Phosphorylation Site and Is Required for Efficient Viral RNA Replication. <i>Journal of Virology</i> , 2001, 75, 9087-9095.	1.5	40
513	TT virus infection in patients with chronic hepatitis B or C: Influence on clinical, histological and virological features. , 2000, 60, 387-392.		28
514	Low incidence of hepatitis C virus transmission between spouses: A prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 391-395.	1.4	51
515	Efficacy of consensus interferon in the treatment of chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1418-1423.	1.4	11
516	Interspousal transmission of TT virus: Low efficiency and lack of apparent risk factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1287-1291.	1.4	0
517	Familial Risk of Hepatocellular Carcinoma Among Chronic Hepatitis B Carriers and Their Relatives. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1159-1164.	3.0	200
518	Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. <i>Gastroenterology</i> , 2000, 119, 431-440.	0.6	215
519	Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. <i>Gastroenterology</i> , 2000, 118, 554-559.	0.6	892
520	Hepatitis B genotypes and the response to interferon therapy. <i>Journal of Hepatology</i> , 2000, 33, 998-1002.	1.8	449
521	Interspousal transmission of TT virus: Low efficiency and lack of apparent risk factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1287-1291.	1.4	0
522	Hepatitis B Virus Infection and Hepatocellular Carcinoma: Molecular Genetics and Clinical Perspectives. <i>Seminars in Liver Disease</i> , 1999, 19, 253-262.	1.8	75

#	ARTICLE	IF	CITATIONS
523	Liver and peripheral blood mononuclear cells are not major sites for GB virus-C/hepatitis G virus replication. <i>Archives of Virology</i> , 1999, 144, 2173-2183.	0.9	11
524	Chromosomal aberrations in nasopharyngeal carcinoma analyzed by comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 1999, 25, 169-175.	1.5	106
525	Characterization of monoclonal antibodies against hepatitis C virus nonstructural protein 3: Different antigenic determinants from human B cells. , 1999, 57, 345-350.		7
526	Decreased diversity of hepatitis C virus quasispecies during bone marrow transplantation. , 1999, 58, 132-138.		19
527	Prevalence and implication of TT virus infection: Minimal role in patients with non-A-E hepatitis in Taiwan. , 1999, 59, 307-312.		42
528	Invasive amoebiasis: an emerging parasitic disease in patients infected with HIV in an area endemic for amoebic infection. <i>Aids</i> , 1999, 13, 2421-2428.	1.0	71
529	Chromosomal aberrations in nasopharyngeal carcinoma analyzed by comparative genomic hybridization. , 1999, 25, 169.		3
530	Hepatocyte growth factor stimulates the growth and activates mitogen-activated protein kinase in human hepatoma cells. <i>Journal of Biomedical Science</i> , 1998, 5, 180-184.	2.6	20
531	Establishment and characterization of NS3 protein-specific T-cell clones from a patient with chronic hepatitis C. <i>Journal of Biomedical Science</i> , 1998, 5, 290-296.	2.6	9
532	Long-term culture of hepatocytes from human adults. <i>Journal of Biomedical Science</i> , 1998, 5, 435-440.	2.6	35
533	BRIEF COMMUNICATION: Efficacy of ribavirin plus interferon alpha on viraemia of GB virus-C/hepatitis G virus: Comparison with interferon alpha alone. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 1249-1253.	1.4	8
534	Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen. <i>Journal of Hepatology</i> , 1998, 28, 915-922.	1.8	59
535	Hepatocyte growth factor stimulates the growth and activates mitogen-activated protein kinase in human hepatoma cells. , 1998, 5, 180.		3
536	Establishment and characterization of NS3 protein-specific T-cell clones from a patient with chronic hepatitis C. , 1998, 5, 290.		1
537	Blood-bank screening for hepatitis G. <i>Lancet, The</i> , 1997, 349, 207.	6.3	10
538	Evolution of hepatitis C virus quasispecies in mothers and infants infected through mother-to-infant transmission. <i>Journal of Hepatology</i> , 1997, 26, 967-974.	1.8	39
539	Molecular biology of hepatitis D virus: Research and potential for application. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, S188-S192.	1.4	16
540	Assembly of Hepatitis Delta Virus-like Empty Particles in Yeast. <i>Virology</i> , 1997, 236, 374-381.	1.1	11

#	ARTICLE	IF	CITATIONS
541	Identification of the Functional Regions Required for Hepatitis D Virus Replication and Transcription by Linker-Scanning Mutagenesis of Viral Genome. <i>Virology</i> , 1997, 239, 119-131.	1.1	32
542	Inhibition of hepatitis delta virus genomic ribozyme self-cleavage by aminoglycosides. <i>Journal of Biomedical Science</i> , 1997, 4, 208-216.	2.6	37
543	Interspousal transmission of GB virus-C/hepatitis G virus: A comparison with hepatitis C virus. <i>Journal of Medical Virology</i> , 1997, 53, 348-353.	2.5	31
544	Hepatitis G Virus Infection in Normal and Prospectively Followed Posttransfusion Children. <i>Pediatric Research</i> , 1997, 42, 784-787.	1.1	14
545	GBV-C/HGV infection and aplastic anaemia. <i>Lancet, The</i> , 1996, 348, 1032-1033.	6.3	11
546	GBV-C in the aetiology of fulminant hepatitis. <i>Lancet, The</i> , 1996, 347, 120-121.	6.3	83
547	Mechanism of vertical transmission of hepatitis G. <i>Lancet, The</i> , 1996, 347, 1116.	6.3	30
548	Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay. <i>Digestive Diseases and Sciences</i> , 1996, 41, 161-165.	1.1	58
549	N-Linked Glycosylation of Hepatitis B Surface Antigens Is Involved but Not Essential in the Assembly of Hepatitis Delta Virus. <i>Virology</i> , 1996, 220, 28-36.	1.1	26
550	Serotyping of hepatitis C virus in chronic type C hepatitis in Taiwan: Correlation with genotypes. <i>Journal of Gastroenterology</i> , 1996, 31, 224-227.	2.3	18
551	Superinfection by homotypic virus in hepatitis C virus carriers: Studies on patients with post-transfusion hepatitis. , 1996, 50, 303-308.		33
552	Phylogenetic Analysis of GB Virus C: Comparison of Isolates from Africa, North America, and Taiwan. <i>Journal of Infectious Diseases</i> , 1996, 174, 410-413.	1.9	54
553	Rapid hepatic failure associated with a contracted liver mimicking cirrhosis in a case of nasopharyngeal carcinoma with liver metastasis. <i>Liver</i> , 1996, 16, 283-287.	0.1	10
554	Serum Hepatitis C Virus Titers in the Progression of Type C Chronic Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 1996, 23, 280-283.	1.1	8
555	Hepatitis C Viral Infection in Thalassemic Children: Clinical and Molecular Studies. <i>Pediatric Research</i> , 1996, 39, 323-328.	1.1	21
556	Genotypes of Hepatitis C Virus in Taiwan and the Progression of Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 1995, 21, 233-237.	1.1	50
557	Inhibition of α -Fetoprotein Production in a Hepatoma Cell Line by Antisense Oligonucleotide Analogues ¹ . <i>Journal of Biochemistry</i> , 1995, 117, 1100-1104.	0.9	6
558	Quasispecies of Hepatitis C Virus and Genetic Drift of the Hypervariable Region in Chronic Type C Hepatitis. <i>Journal of Infectious Diseases</i> , 1995, 172, 261-264.	1.9	53

#	ARTICLE	IF	CITATIONS
559	Prevalence, Genotypes and Antibody Titer of Hepatitis C Virus in Pregnant Women in Taiwan. <i>Journal of Obstetrics and Gynaecology (Tokyo, Japan)</i> , 1995, 21, 557-562.	0.1	4
560	Evaluation of Third-Generation Hepatitis C Antibody Assay in Chronic Hepatitis C and Chronic Non-B, Non-C Hepatitis. <i>Viral Immunology</i> , 1995, 8, 135-139.	0.6	2
561	Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. <i>Journal of Pediatrics</i> , 1995, 126, 589-591.	0.9	188
562	Detection of Divergent Hepatitis C Virus Envelope Sequences. <i>Journal of Biomedical Science</i> , 1994, 1, 158-162.	2.6	0
563	Possible Role of High-Titer Maternal Viremia in Perinatal Transmission of Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 1994, 169, 638-641.	1.9	163
564	Mixed Infections Of Hepatitis C Virus As A Factor In Acute Exacerbations Of Chronic Type C Hepatitis. <i>Journal of Infectious Diseases</i> , 1994, 170, 1128-1133.	1.9	71
565	Isoprenylation of Large Hepatitis Delta Antigen Is Necessary but Not Sufficient for Hepatitis Delta Virus Assembly. <i>Virology</i> , 1994, 199, 169-175.	1.1	76
566	Detection of divergent hepatitis C virus envelope sequences. <i>Journal of Biomedical Science</i> , 1994, 1, 158-162.	2.6	3
567	Characterization of T cell clones specific to a determinant of hepatitis B virus core and e antigens in chronic type B hepatitis: Implication for a T cell mechanism of HBV immunopathogenesis. <i>Journal of Biomedical Science</i> , 1994, 1, 105-118.	2.6	8
568	Inverse polymerase chain reaction for cloning cellular sequences adjacent to integrated hepatitis B virus DNA in hepatocellular carcinomas. <i>Journal of Virological Methods</i> , 1994, 49, 269-284.	1.0	30
569	Immune response to a hepatitis C virus nonstructural protein in chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 1994, 21, 403-411.	1.8	26
570	Temporal profile of hepatitis C virus antibody and genome in infants born to mothers infected with hepatitis C virus but without human immunodeficiency virus coinfection. <i>Journal of Hepatology</i> , 1994, 20, 641-645.	1.8	49
571	A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan: comparison between posttransfusion and sporadic patients. <i>Journal of Hepatology</i> , 1994, 21, 244-249.	1.8	36
572	Posttransfusion hepatitis C virus infection in children. <i>Journal of Pediatrics</i> , 1994, 124, 709-713.	0.9	49
573	Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation. <i>Gastroenterology</i> , 1994, 107, 1514-1518.	0.6	86
574	Hepatitis C Virus Infection in Pregnant Women: Detection by Different Anti-HCV Immunoassays and Serum HCV-RNA. <i>Asia-Oceania Journal of Obstetrics and Gynaecology</i> , 1994, 20, 13-18.	0.0	2
575	Age-Specific Prevalence of Hepatitis B Surface and e Antigenemia in Pregnant Women in Taiwan. <i>Asia-Oceania Journal of Obstetrics and Gynaecology</i> , 1994, 20, 141-145.	0.0	7
576	Comparison of Three Different Immunoassays and PCR for the Detection of Hepatitis C Virus Infection in Pregnant Women in Taiwan. <i>Vox Sanguinis</i> , 1993, 65, 117-121.	0.7	11

#	ARTICLE	IF	CITATIONS
577	Hepatitis Delta Virus cDNA Monomer Can Be Used in Transfection Experiments to Initiate Viral RNA Replication. <i>Virology</i> , 1993, 197, 137-142.	1.1	26
578	Immunoglobulin M antibodies against hepatitis C virus antigens: significance and applications. <i>Gastroenterologia Japonica</i> , 1993, 28, 67-70.	0.4	1
579	Sexual transmission of HCV. <i>Lancet, The</i> , 1993, 342, 626.	6.3	16
580	Cytogenetic studies on human liver cancer cell lines. <i>Cancer Genetics and Cytogenetics</i> , 1993, 65, 161-166.	1.0	22
581	Hepatitis B Virus in the Colostra of HBeAg-Positive Carrier Mothers. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1993, 17, 207-210.	0.9	39
582	Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis. <i>Gastroenterology</i> , 1993, 105, 583-587.	0.6	93
583	Comparison of Three Different Immunoassays and PCR for the Detection of Hepatitis C Virus Infection in Pregnant Women in Taiwan. <i>Vox Sanguinis</i> , 1993, 65, 117-121.	0.7	11
584	Intrafamilial Transmission of Hepatitis C Virus: The Important Role of Infections between Spouses. <i>Journal of Infectious Diseases</i> , 1992, 166, 900-903.	1.9	148
585	The Taiwanese hepatitis C virus genome: Sequence determination and mapping the 5' termini of viral genomic and antigenomic RNA. <i>Virology</i> , 1992, 188, 102-113.	1.1	210
586	Inactivation of the retinoblastoma gene in acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 1992, 82, 502-507.	1.2	32
587	Cellular Immune Response to HBcAg in Mother-to-Infant Transmission of Hepatitis B Virus. <i>Hepatology</i> , 1992, 15, 770-776.	3.6	126
588	Temporal aspects of major viral transcript expression in hep G2 cells transfected with cloned hepatitis B virus DNA: With emphasis on the X transcript. <i>Virology</i> , 1991, 185, 644-651.	1.1	35
589	Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood. <i>Hepatology</i> , 1991, 13, 316-320.	3.6	83
590	Isolation of a complementary DNA fragment of hepatitis C virus in Taiwan revealed significant sequence variations compared with other isolates. <i>Hepatology</i> , 1991, 14, 73-78.	3.6	35
591	Low prevalence of hepatitis C virus and infrequent perinatal or spouse infections in pregnant women in Taiwan. <i>Journal of Medical Virology</i> , 1991, 35, 237-240.	2.5	26
592	Hepatitis C virus infection in Taiwan. <i>Gastroenterologia Japonica</i> , 1991, 26, 164-166.	0.4	29
593	Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood. <i>Hepatology</i> , 1991, 13, 316-320.	3.6	8
594	Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children. <i>Hepatology</i> , 1990, 12, 657-660.	3.6	84

#	ARTICLE	IF	CITATIONS
595	Characterization of the Transcripts of Hepatitis D and B Viruses in Infected Human Livers. Journal of Infectious Diseases, 1989, 160, 944-947.	1.9	5
596	Postpartum subsidence of hepatitis B viral replication in hbeag-positive carrier mothers. Journal of Medical Virology, 1989, 29, 1-6.	2.5	58
597	Clonal Origin of Recurrent Hepatocellular Carcinomas. Gastroenterology, 1989, 96, 527-529.	0.6	130
598	Characterization of the spectrum of postthymic T-cell malignancies in Taiwan a clinicopathologic study of HTLV-1-positive and HTLV-1-negative cases. Cancer, 1988, 61, 2060-2070.	2.0	52
599	Status of hepatitis B virus DNA in hepatocellular carcinoma: A study based on paired tumor and nontumor liver tissues. Journal of Medical Virology, 1988, 25, 249-258.	2.5	29
600	Î Infection in asymptomatic carriers of hepatitis B surface antigen: Low prevalence of Î activity and effective suppression of hepatitis B virus replication. Hepatology, 1988, 8, 1121-1124.	3.6	56
601	Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct-acting antiviral-induced sustained virologic response. Advances in Digestive Medicine, 0, , .	0.1	3